Iveric Bio Inc.

Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition

Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more

Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more

Plus: Innovent hires Nageatte Ibrahim as oncology CMO, and updates from Endeavor and Vittoria

Plus: Arcutis hires Topper as CFO and Snehal Shah becomes R&D president at

Plus: Jason Gammack named CEO of Ansa, and updates from LenioBio, Prothena and Ikena

Plus: New CFO for Innovent and updates from Takeda, Shionogi, Lexeo, Stuart, Arcellx and more

Led by Chen Yu, firm launched in 2021 exceeds planned target for Fund II after string of M&A deals brings returns

Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more

Mature assets have been a theme among this year’s $1B+ takeouts, but Mirati fetched one of the lowest premiums despite its marketed product